RxCell has announced a US patent for its induced pluripotent stem cells (iPSCs)-based cell therapy approach, a method of ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

Through TF-based cell fate programming, TFome is designed to yield first-in-class and best-in-class off-the-shelf cell therapy products up to 100 times more rapidly than conventional methods of cell ...

CAR T-cell therapy carried a risk of second primary malignancy (SPM) that was no worse than that of other standard-of-care ...

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

A drug production facility in Durham run by a Chinese company violated multiple safety regulations, according to the FDA. A ...

While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, ...

Trailhead Biosystems Inc. announced Monday, Sept. 16, that it has hired Joshua Snow as chief commercial officer. The ...

The EBMT is proud to announce that its Registry has achieved a landmark milestone of 10,000 chimeric antigen receptor T-cell (CAR-T) therapy patients. This significant achievement underscores the ...

NAD IV therapy is an effective and unique solution that is designed to address health and energy at the molecular level.

About Neurona Therapeutics Neurona is developing allogeneic, off-the-shelf, regenerative neural cell therapy products with the potential to provide long-term targeted repair of the nervous system ...